Eli Lilly's Oral GLP-1 Pill Outperforms Rival Diabetes Drugs in Trials

Eli Lilly (NYSE: LLY) announced that its experimental oral GLP-1 pill Foundayo (orforglipron) achieved superior results compared to competing therapies from Novo Nordisk and AstraZeneca in three late-stage Phase 3 trials for type 2 diabetes. The pill demonstrated better blood sugar control and greater weight loss.

The Product

Foundayo is an oral GLP-1 receptor agonist, the first oral therapy in its class to show superiority over injectable competitors in late-stage trials. It works by stimulating GLP-1 receptors, boosting insulin secretion and reducing appetite.

Pricing and Availability

Eli Lilly has not yet disclosed pricing or a launch timeline for Foundayo. The company is expected to file for FDA approval within the next year.

Competition

Foundayo faces competition from Novo Nordisk's injectables Ozempic and Wegovy, as well as AstraZeneca's oral therapies. However, its trial superiority could give it a significant edge in the over $100 billion diabetes and obesity market.

Potential Impact on the Company

Success of Foundayo could strengthen Eli Lilly's position in the diabetes and obesity drug market and boost LLY stock. However, regulatory and manufacturing risks remain.